Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
Teva has told Generics Bulletin that it plans to file an appeal before the Court of Justice of the European Union’s General Court after it and its Cephalon subsidiary were together fined €60.5m ($72m) by the European Commission over an historic ‘pay-for-delay’ arrangement covering Cephalon’s Provigil (modafinil).
According to findings just published by the Commission, via a December 2005 patent settlement agreement covering secondary Provigil patents, Cephalon...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
